1. FDA Committee Votes 6-6 on Durect's Non-Opioid Pain Drug — Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 — Novo Nordisk's Ozempic wins FDA label boost with CV indication — See more on our front page news TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Insider Raiding

Discussion in 'Alza' started by Anonymous, Jul 22, 2008 at 7:43 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    For those who don't already know, the total end of Alza should come within two years.

    JNJ has begun transferring manufacturing of all the biggest profit generating products to other sites like Gurabo. For example, Sudafed is gone, Concerta is gone, Invega is gone. More will follow.

    Basically, JNJ is moving out all the OROS products, but Alza will regain all the transdermal stuff, like Duragesic and Nicotine.

    Unfortunately, Alza will now try to go it as a 'profit center,' relying on partners for products to be manufactured and taking a cut of the profits.

    IMHO, it won't work because the small slice that Alza will receive will not be enough to maintain the critical mass of employees needed to be successful.

    Alza is a top heavy, inefficient operation. Only now is Alza beginning to adopt JNJ culture and practices (too little too late).

    Farewell my concubine.

  2. Anonymous

    Anonymous Guest

    When JNJ bought Alza, that was the end of Alza. That bunch in Palo Alto lived in their own little dream world, thought the world revolved around them.
  3. Anonymous

    Anonymous Guest

    Why so bitter, make your life today and look forward.
  4. Anonymous

    Anonymous Guest

    You hit the nail on the head, "that bunch in Palo Alto lived in their own little world." It was a dream world and they got mad @ anyone making change and trying to help them. They all hated the sales force.
  5. Anonymous

    Anonymous Guest

    Just how exactly where you brainiacs going to help the folks in Palo Alto? JNJ can sell the hell out of band-aids and baby shampoo, but they do not know a thing about selling pharmaceuticals. Alza produced innovative products and sold the hell out of them, while JNJ spent more time in sales meetings on Safe freaking fleet than they did on sales. Everytime JNJ acquires a decent company they screw it up with their ass kissing corporate climbing MBA's. I am surprised Centocor lasted as long as it did. Those same JNJ mBA's overpaid for ALZA, and there are a bunch of us that still have a bunch of JNJ stock being fed by everything other than JNJ pharma. If you idiots could figure that one out we would all benefit. Stop worrying about your career and do your job.